- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04264871
Is the Preoperative Preparation of Sickle Cell Patients Optimal: Assessment of Practices and Post-operative Complications
Is the Preoperative Preparation of Sickle Cell Patients Optimal: Retrospective Assessment of Practices and Post-operative Complications in a Cohort of Children Followed at Hôpital Universitaire Des Enfants Reine Fabiola (HUDERF) and Who Have Been Managed According Local Guidelines Including Transfusion or Exchange Transfusion Before Surgery
Children with sickle cell disease systematically receive a transfusion 2 to 5 days before scheduled surgery (with the exception of minor surgeries) in order to avoid post-operative complications of which the vaso-occlusive crisis and acute thoracic syndrome are the most frequent.
This standardized preoperative protocol was established on the basis of the results of large-scale randomized studies, most of which date back over ten years, and which have demonstrated the beneficial effects of transfusion (or transfusion exchange) preoperatively. To date, several other more recent studies (but not controlled) have questioned this type of systematic management.
The purpose of this study is to review retrospectively data of sickle cell children who have undergone elective surgery at the Huderf in the last ten years and to identify the eventual complications encountered. The most common procedures in these patients are: tonsillectomy with or without associated adenoids, splenectomy and cholecystectomy.
General data on sickle cell disease (history, genotype, G6PD deficiency, biology and previous complications), pre-surgical preparation, surgery and post surgical management and complications will be collected and analyzed.
This retrospective analysis will allow an objective assessment of the current quality of care and will provide useful data to improve patient management.
Studieoversikt
Status
Forhold
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
Brussles
-
Brussels, Brussles, Belgia, 1020
- Hôpital Universitaire Des Enfants Reine Fabiola
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Sickle cell disease with surgery during the 2010-2019 period
Exclusion Criteria:
- None
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Retrospektiv
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To assess the overall incidence of vaso-occlusive-events 1 month post surgery
Tidsramme: 1 month after surgery
|
Vaso-occlusive-events will include Vaso Occlusive Crisis (acute pain events that requires a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs)), acute chest syndrome (new pulmonary infiltrate associated with by pneumonia-like symptoms, pain or fever) and hemoglobin < 6g/dl
|
1 month after surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To assess the incidence of Vaso Occlusive Crisis 1 month post surgery
Tidsramme: 1 month after surgery
|
Vaso Occlusive Crisis is defined as acute pain events that requires a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs)
|
1 month after surgery
|
|
To assess the incidence of Vaso Occlusive Crisis 3 months post surgery
Tidsramme: 3 months after surgery
|
Vaso Occlusive Crisis is defined as acute pain events that requires a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs)
|
3 months after surgery
|
|
To assess the incidence of Vaso Occlusive Crisis 12 months post surgery
Tidsramme: 12 months after surgery
|
Vaso Occlusive Crisis is defined as acute pain events that requires a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs)
|
12 months after surgery
|
|
To assess the incidence of Acute Chest Syndrome 1 month post surgery
Tidsramme: 1 month after surgery
|
Acute Chest Syndrome is defined as a new pulmonary infiltrate associated with by pneumonia-like symptoms, pain or fever
|
1 month after surgery
|
|
To assess the incidence of Acute Chest Syndrome 3 months post surgery
Tidsramme: 3 months after surgery
|
Acute Chest Syndrome is defined as a new pulmonary infiltrate associated with by pneumonia-like symptoms, pain or fever
|
3 months after surgery
|
|
To assess the incidence of Acute Chest Syndrome 12 months post surgery
Tidsramme: 12 months after surgery
|
Acute Chest Syndrome is defined as a new pulmonary infiltrate associated with by pneumonia-like symptoms, pain or fever
|
12 months after surgery
|
|
To assess the duration of hospitalization post-surgery
Tidsramme: 1 month after surgery
|
number of days between surgery and day of discharge
|
1 month after surgery
|
|
To assess the incidence of Red Blood Cell (RBC) allo-immunization 1 month post surgery
Tidsramme: 1 month after surgery
|
incidence of acute anemia with the presence of new allo-antibody(ies) against RBC
|
1 month after surgery
|
|
To assess the incidence of RBC allo-immunization 3 months post surgery
Tidsramme: 3 months after surgery
|
incidence of acute anemia with the presence of new allo-antibody(ies) against RBC
|
3 months after surgery
|
|
To assess the incidence of RBC allo-immunization 12 months post surgery
Tidsramme: 12 months after surgery
|
incidence of acute anemia with the presence of new allo-antibody(ies) against RBC
|
12 months after surgery
|
|
To assess the number of RBC transfusion episodes 1 month post surgery
Tidsramme: 1 month after surgery
|
Number of RBC unit transfused
|
1 month after surgery
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Alina Ferster, MD, Queen Fabiola Children's University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P2020/Hemato/SCDPreop
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .